Companies /Healthcare
Humana Inc
NYSE: HUM Healthcare Plans
$380.10
▼ $5.69 (−1.47%) today
Markets closed · 6:08pm ET

Humana (HUM) Q3 2026 Earnings

Reported Nov 6, 2026, 6:09am ET · SEC source
$-0.70
Beat +30.33%
EPS · est. $-1.00 Adjusted

Adjusted figure excludes a $358 million pretax put/call valuation gain on non-consolidating minority interest investments ($2.94 per share), $25 million of value creation initiative charges ($0.21), $10 million of intangible amortization ($0.07) and $3 million of impairment charges ($0.03), with a $0.61 net tax impact; GAAP diluted EPS was $1.33

$41.2B
Beat +0.65%
Revenue · est. $40.9B
6 quarters
Consecutive EPS beats

How Did HUM Stock React to Q3 2026 Earnings?

% change · around the report
0+3%+6%Nov 6Nov 6report 6:09am ETearnings+0.0%+4.7%
0+3%+6%Nov 6Nov 6earnings+0.0%+4.7%
HUM +4.7%S&P 500 +0.0%
0+3%+6%Nov 6Nov 6report 6:09am ETearnings−0.0%+4.7%
0+3%+6%Nov 6Nov 6earnings−0.0%+4.7%
HUM +4.7%NASDAQ −0.0%
0+4%+8%Nov 5Nov 12report 6:09am ETearnings+3.0%+8.5%
0+4%+8%Nov 5Nov 12earnings+3.0%+8.5%
HUM +8.5%S&P 500 +3.0%
0+4%+8%Nov 5Nov 12report 6:09am ETearnings+4.6%+8.5%
0+4%+8%Nov 5Nov 12earnings+4.6%+8.5%
HUM +8.5%NASDAQ +4.6%
+5.33%
Day of report
−2.43%
Next session
+3.75%
One week

Did HUM Beat Earnings? Q3 2026 Results

Yes. Humana reported Q3 2026 earnings of $-0.70 a share on Nov 6, 2026, beating the $-1.00 consensus estimate by 30.3%. Revenue was $41.2B against a $40.9B estimate.

Humana delivered a stronger-than-expected third quarter for fiscal 2026, posting an adjusted loss of $0.70 per share against a consensus estimate of a $1.00 loss, a beat of 30.33% that extended the company's streak of topping Wall Street EPS forecasts to five consecutive quarters. Revenue climbed 26.1% year over year to $41.16 billion, edging past the $40.89 billion consensus by 0.65%. The outperformance was driven primarily by better-than-anticipated Insurance segment results, where the benefit ratio came in at 93.7%, ahead of management's own guidance of slightly above 94%, even as it remained elevated compared to 91.1% a year earlier amid ongoing Medicare Advantage cost pressures and a significantly smaller favorable prior-period reserve development of $67 million versus $275 million in the prior year. Individual Medicare Advantage membership grew roughly 23% year to date, adding around 1.21 million members. Encouraged by the quarterly performance, management raised its full-year 2026 adjusted EPS guidance to at least $9.50 from at least $9.00, while analysts had already flagged improving 2027 star ratings as a catalyst for higher government bonuses in 2028.

Key Takeaways
  • Medicare membership growth across individual MA, group MA and stand-alone PDP in 2026
  • Higher per-member individual MA and PDP premiums from increased CMS MA benchmark funding and the IRA-driven Part D direct subsidy
  • 2026 individual MA pricing and clinical excellence efforts more than offsetting claims trend
  • Group MA recontracting benefits for the 2026 plan year
  • Insurance segment benefit ratio of 93.7%, favorable to guidance of 'slightly above 94 percent'
  • Medical and pharmacy cost trends in line to better than 'high single digit' expectations across new and existing membership
  • 3Q26 adjusted loss per share of $0.70 ahead of guidance of an approximately $1.00 loss
  • Operating cost ratio improvement from operating leverage, tactical cost cutting and transformation initiatives; YTD adjusted consolidated operating cost ratio of 10.3%, down 80 bps
  • Lower favorable prior-period reserve development: $67 million in 3Q26 vs $275 million in 3Q25
  • Insurance segment GAAP loss from operations of $303 million vs income of $251 million a year ago
  • CenterWell operating income pressured by the final year of the v28 phase-in, elevated primary care costs in one geography and a higher specialty pharmacy mix
  • Put/call valuation adjustment gain of $358 million pretax boosting GAAP results
  • YTD CenterWell Pharmacy revenue growth of 18% from membership growth, mail order penetration and agnostic Specialty, Direct to Consumer and Direct to Employer volumes
  • Home health episodic admissions up 9.5% year over year in 3Q26; same-store total admissions up 5.5%

“Humana is delivering positive results for our members, our patients and their health.”

Humana CEO, on the earnings call

What Is Humana's Outlook?

Humana raised FY 2026 Adjusted EPS guidance to 'at least $9.50' from 'at least $9.00' and revised GAAP EPS guidance to 'at least $15.09' from 'at least $6.52'. The adjusted outlook still anticipates a year-over-year decline due to the BY 2026 Star Ratings headwind, net of mitigation. GAAP guidance includes two items tied to the HPS/BlackRock CenterWell Senior Primary Care JV, expected to be recorded in Q4 2026: - a noncash reversal of an approximately $1.2 billion net put liability; - a new initial option liability ($2.14 per share). All other guidance is unchanged: - Revenue: consolidated revenues of at least $160 billion; Insurance segment at least $155 billion; CenterWell segment at least $25 billion. - Membership: individual MA growth of approximately 25 percent; group MA growth of approximately 150,000; stand-alone PDP growth of approximately 1,000,000; state-based contracts growth of 25,000 to 100,000. - Ratios: Insurance segment benefit ratio of 92.75% +/- 25 bps; consolidated operating cost ratio of 10.0% +/- 25 bps. - Segment income: Insurance segment income from operations approximately breakeven; CenterWell segment income from operations of $1.3–$1.8 billion GAAP ($1.5–$2.0 billion non-GAAP). - Other: effective tax rate approximately 25.5%; approximately 121 million diluted shares; operating cash flows of $2.5–$2.9 billion; capital expenditures approximately $650 million. Fourth-quarter seasonality: the Insurance segment benefit ratio is expected to be just above 95.5%, with the consolidated benefit ratio slightly above that. Longer-term outlook: - Management expects its 2027 individual MA bid approach to drive meaningful progress toward a sustainable pre-tax margin of at least 3% in 2028. - It plans to manage 2028 products and expenses at approximately Top Quartile Stars levels. - It expects the CenterWell JV to reduce GAAP debt-to-capitalization by about 130 bps in Q4 2026, and further in 2027 and 2028. - A virtual investor update is scheduled for December 10, 2026. The company expects potential further changes to GAAP EPS guidance from value creation and other strategic initiatives, but no changes to Adjusted EPS guidance.

HUM YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$20.0B$40.0B$32.6B$41.2BRevenue$134.0M$75.0MOperating Income$195.0M$162.0MNet Income
$0$20.0B$40.0BRevenueOperating IncomeNet Income
HUM income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $41.2B $32.6B +26.1%
Operating Income $75.0M $134.0M −44.0%
Net Income $162.0M $195.0M −16.9%

HUM Revenue by Segment

Individual Medicare Advantage$28.6B+27.4%
CenterWell Pharmacy Solutions$4.1B+20.4%
State-Based Contracts and Other$3.6B−2.4%
Medicare Stand-Alone PDP$3.0B+71.7%
Group Medicare Advantage$2.8B+24.7%
CenterWell Primary Care$2.1B+37.2%
CenterWell Home Solutions$880.0M−0.6%
Medicare Supplement$363.0M+28.3%

When Does Humana Report Next?

Expected report date
After the close
Release timing

Figures from SEC filings and company reports. Not investment advice.